How Does 22nd Century Group Inc (XXII) Stock Compare to Others in Drug Manufacturers - Specialty & Generic?

Thursday, July 2, 2020 2:46 PM | InvestorsObserver Analysts

The 7 rating InvestorsObserver gives to 22nd Century Group Inc (XXII) stock puts it near the bottom of the Drug Manufacturers - Specialty & Generic industry. In addition to scoring higher than 17 percent of stocks in the Drug Manufacturers - Specialty & Generic industry, XXII’s 7 overall rating means the stock scores better than 7 percent of all stocks.

Overall Score - 7
XXII has an Overall Score of 7. Find out what this means to you and get the rest of the rankings on XXII!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With 22nd Century Group Inc Stock Today?

22nd Century Group Inc (XXII) stock is down -1.21% while the S&P 500 is up 1.03% as of 2:37 PM on Thursday, Jul 2. XXII is lower by -$0.01 from the previous closing price of $0.75 on volume of 574,959 shares. Over the past year the S&P 500 is up 5.07% while XXII is lower by -63.18%. XXII lost -$0.22 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for 22nd Century Group Inc click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Related Companies